Cholesterol Conversations
How Do We Get There from Here: Partnering with Patients to Achieve LDL Goals
Mar 8, 2023
Drs. Marc Bonaca, Pam Taub, and Heather Johnson talk about multiagent therapy for cholesterol treatment and the efficacy of novel agents. They emphasize the importance of shared decision-making, managing high-risk populations, and simplifying prior authorization. They also discuss the benefits of a team approach in lipid management and the potential of non-statin options like Bempedoic acid.
19:16
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Combination therapy, including alternative options like Bempedoic acid, is crucial for achieving target LDL levels and improving outcomes in high-risk patients.
- Bempedoic acid offers a safe and effective non-statin option for lowering LDL cholesterol with minimal risk of diabetes, especially for patients unable to tolerate statins.
Deep dives
Importance of Aggressively Modifying LDL Cholesterol in Clinical Practice
In the podcast, Dr. Pam Togham highlights the significance of lowering LDL cholesterol and the need for aggressive risk modification. Despite the availability of multiple therapies, clinical practice often falls short in achieving target LDL levels recommended by guidelines. Statin monotherapy, the traditional approach, is no longer sufficient. Dr. Togham emphasizes the importance of combination therapy and alternative options like Bempedoic acid for patients unable to tolerate statins. The breakthrough study of clear outcomes demonstrates the efficacy of Bempedoic acid in reducing mace events, LDL cholesterol, and high sensitive CRP levels. This study provides an effective non-statin option for high-risk patients.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
